[3][4] Phase 2 clinical trials demonstrated a safety profile generally consistent with the GLP-1/GIP/glucagon agonist class, with no unexpected safety signals during the 48-week study period
Therapeutic Package ($399/month) Our most common dosing range for consistent, ongoing weight loss
Impurities 1.0% (see CoA)
Clinical protocols typically start at 1ml weekly for four weeks, then adjust based on patient-reported energy levels, serum homocysteine trends, and weight loss velocity
This enhances its impact on cognitive function, making it a preferred choice for neurological support.
Semaglutide is not on Indias National List of Essential Medicines and lacks public health scheme coverage, meaning patients pay entirely out of pocket